KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $61,890.75 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 3,975 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the transaction, the insider owned 47,003 shares in the company, valued at $731,836.71. The trade was a 7.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock opened at $15.76 on Friday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The firm has a 50-day moving average of $15.50 and a 200-day moving average of $13.97. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.23 and a 52-week high of $19.00. The stock has a market cap of $796.60 million, a PE ratio of -3.99 and a beta of -0.19.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KALV. HC Wainwright lifted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Needham & Company LLC lifted their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at about $55,000. Wolverine Asset Management LLC bought a new position in KalVista Pharmaceuticals in the third quarter valued at about $57,000. Truvestments Capital LLC grew its position in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,360 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in KalVista Pharmaceuticals during the third quarter worth about $63,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.